Healthcare Unfiltered Express

Dr. Amer Zeidan joins the Healthcare Unfiltered EXPRESS to discuss the recently published KOMET-007 trial, which made its way to print in Blood . Dr. Zeidan discusses how Menin inhibitors are transforming how we approach AML like no other therapies before. What does the future hold and how will the results of this trial affect therapy? The KOMET-007 trial is a Phase 1/2 clinical study evaluating t...

On this Healthcare Unfiltered EXPRESS, Dr. Arturo Bonilla, CMO of Massive Bio and an AI oncologist expert who leads many AI efforts nationally, joined Chadi to provide his insights on where AI is being applied in patient care. He gives timely use case examples that will resonate with everyone. AI is here to stay and we must know where and how it applies. Please join the conversation, subscribe, li...

Dr. Virginia Kaklamani joins Healthcare Unfiltered EXPRESS to discuss the recent FDA-approved indications for T-DXd in breast cancer, and what this means for treating patients with the disease. A critical episode ahead of the annual ASCO meeting. Check it out, subscribe, rate, review, and join the conversation.

Dr. Rani Bansal of Duke University joins the show to share her insights on the latest ESMO Breast meeting that concluded in Berlin. Dr. Rani shares data on the top 5 abstracts that may change or inform practice. Check it out, share, subscribe, and join the conversation.

Dr. Emily Landon of the University of Chicago joins the show to explain everything you must know about the Hantavirus - should we be concerned? What to do? What not to do? Is this another COVID? Get the facts right here, and please share, subscribe, and join the conversation.

Dr. Deva Mahalingam shares on Healthcare Unfiltered EXPRESS a new paper published in Nature Medicine on a regimen showing significant promise in pancreatic cancer. You want to listen to this podcast and check out the paper. https://www.nature.com/articles/s41591-026-04327-4 Share, subscribe, and join the conversation.

Dr. Matt Davids of the Dana Farber Cancer Institute joins Healthcare Unfiltered EXPRESS to share his data-solidified insights on navigating the treatment of relapsed/refractory (R/R) CLL, considering the welcome advances the field has witnessed in treating front-line disease. Check it out, subscribe, rate, and join the conversation.

Dr. Vincent Rajkumar of the Mayo Clinic joins the Healthcare Unfiltered EXPRESS to highlight a major study recently published in the NEJM concerning patients with R/R multiple myeloma. This study is arguably changing the standard of care for relapsed disease. We discussed the study, its rationale, its implications, and limitations. Here is a link to the actual publication: https://www.nejm.org/doi...

Dr. Andrea Apolo from the NCI and the co-Chair of the ASCO GU 2026 scientific program joined the Healthcare Unfiltered EXPRESS to share what she viewed as potentially practice-changing data in bladder cancer. She discussed what she viewed as the top 4 abstracts to be aware of. Stay up to date on all oncology meetings by subscribing to Healthcare Unfiltered EXPRESS; share with colleagues, and join...

Dr. Shilpa Gupta of Cleveland Clinic joins Healthcare Unfiltered EXPRESS to share three major abstracts from the ASCO-GU-2026 meeting that could change clinical practice in kidney and prostate cancers. Dr. Gupta brings this data home by explaining their impact on real-world practices. Check these out, subscribe, review, and join the conversation.

Dr. Eric Singhi of the MD Anderson Cancer Center joins Healthcare Unfiltered EXPRESS to describe this newly approved drug, its target, the trial that led to its approval, and how it fits into the treatment armamentarium for lung cancer. Please rate, subscribe, share, and join the conversation.

Arguably, the development and approval of Menin Inhibitors in AML are one of the most important advances in this disease in the past 1-2 years. Dr. Uma Borate joins Healthcare Unfiltered EXPRESS and shares with us everything we must know about this class of drugs: how they are used, their toxicities, and what the future of AML management may look like now that we have Menin inhibitors. Check it ou...

Dr. Marc Braunstein from NYU Langone joins the Healthcare Unfiltered EXPRESS to describe the recently published BRUIN-313 trial in frontline CLL and its potential impact on the treatment landscape for this disease. Check it out, subscribe, share, and join the conversation.

Dr. Ishwaria Subbiah joined the Healthcare Unfiltered EXPRESS to discuss burnout, a problem physicians and many other healthcare providers face. She offers that AI and technology may bring solutions to reduce this problem and improve satisfaction. Check it out, subscribe, review, share, and join the conversation.

Dr. Sara Tolaney of the Dana-Farber Cancer Institute joined the show to share her insights on the ASCENT-04 trial recently published in NEJM . This is an RCT in triple-negative breast cancer. Sara led this study and as the lead author, she puts its results in context - this is a must-listen episode. Please share, review, and subscribe.

Dr. Ajay Nooka of Emory University and the Winship Cancer Institute joins Healthcare Unfiltered EXPRESS to tell us about CELMoDs in multiple myeloma. What are these agents? How do they work? How do they help patients with myeloma? And what does the future of this disease look like now that we may have CELMoDs for this disease? A must listen, and please share your comments.

Dr. Kasi from the City of Hope joins the Healthcare Unfiltered EXPRESS for a chat on what intrigued him at the last ASCO GI meeting that took place a few weeks ago. What mattered and did any standards of care changed? Take a listen, share, subscribe, review, and join the conversation.

Dr. Dan Olson of the University of Chicago joins the Healthcare Unfiltered EXPRESS to discuss the current state of TILs in cancer therapy, specifically in melanoma. Dr. Olson describes the technology, how to deliver, how to mitigate side effects, and offers valuable insights on future directions. A mist listen - please share, review, and subscribe.

Dr. Erika Hamilton from the SCRI joined the show to give timely and important updates on how treating breast cancer may be changing in view of trial data presented at the 2025 December SABCS meeting that just concluded. A must listen episode to stay up to date with new emerging data and therapies in breast cancer. Please share and subscribe.

Dr. Julio Chavez of the Mayo Clinic joins the Healthcare Unfiltered EXPRESS to explain data on this class of drugs, their mechanism of action, and where they fit in the treatment armamentarium of various lymphomas. The best way to stay up to date is to subscribe and share.

Dr. Vincent Rajkumar of the Mayo Clinic visits the Healthcare Unfiltered EXPRESS to review published data on what constitutes myeloma on the molecular and genomic level. Turns out that some patients that we thought do not have myeloma, they indeed have the disease. A must listen and a provocative episode. Please rate, share, and subscribe

I am joined by Dr. Erica Conroy, CEO of Primm.co, and Dr. Matt Kurian, a breast medical oncologist. They both share the importance of curbside consults between oncologists at the point of care. Erica leads an innovative company that allows exchange of ideas, opinions, and aid to healthcare professionals to navigate the complexity of medical oncology by seeking consults form peers and KOLs exactly...

Dr. Mazyar Shadman joined Healthcare Unfiltered EXPRESS to share his insights on data-driven approaches to treating CLL in the front-line setting. Timely podcast as we approach the annual ASH 2025 meeting. Check it out, subscribe, and join the conversation.

Dr. Matt Lunning from the University of Nebraska simplifies how best we approach these aggressive diverse collections of lymphomas. Concise and straight to the point; check it out, subscribe, and join the conversation.

Dr. Matthew Kurian joins Healthcare Unfiltered EXPRESS to share his observations and insights on new emerging targets in breast cancer and how these targets are driving treatment selection across all disease stages. Please subscribe, review, and join the conversation.